The Indian Institute of Chemical Technology (IICT) here and city-based Lee Pharma, an integrated pharmaceutical company, have entered into a non-exclusive licensing agreement for the synthesis of 2-De
CSIR-IICT, Lee Pharma join hands to produce 2-DG drug for Covid-19 patients
CSIR-IICT, Lee Pharma join hands to produce 2-DG drug for Covid-19 patients
Hyderabad-based CSIR-IICT and Lee Pharma have signed an agreement for synthesis of DRDO-developed anti-Covid drug 2-DG.
advertisement
UPDATED: June 9, 2021 18:54 IST
2-DG, developed by DRDO and Dr Reddy’s Laboratories, has received approval for use in Covid-19 treatment. (Photo: India Today/Manjeet Negi)
Hyderabad-based Indian Institute of Chemical Technology, a constituent laboratory of Council of Scientific and Industrial Research (CSIR-IICT,) and pharmaceutical company Lee Pharma have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG).
Lee Pharma informed they would file application for getting approval from drug regulator.(FILE)
New Delhi:
Hyderabad-based Lee Pharma has entered into an agreement with the Indian Institute of Chemical Technology (IICT), a constituent laboratory of CSIR, to manufacture and commercialise 2-Deoxy-D-Glucose (2-DG) used to treat Covid patients, a statement said on Wednesday.
An integrated pharmaceutical company, Lee Pharma entered into the non-exclusive licensing agreement for the synthesis of 2-DG, recently developed by DRDO and Dr Reddy s Laboratories.
The drug has received approval for use in COVID-19 patients. It has been found to help speed up recovery and reduce oxygen dependence, and Dr. Reddy s Laboratories has launched the drug in the form of sachets.